I received a PM and was urged by the sender to pos

Quote:

---

I assume that the LL regulation list is the foundation for the disease list. But what is the source/foundation for the regulation list? You obviously had to have had something to work with that permitted you to gain such insights regarding the MOA of a particular drug. Perhaps you have already discussed this long ago in other posts. If so, I apologize, but it strikes me that now might be a good time for you to post (or remind us), in as elementary a manner as possible, regarding the source materials that have allowed you, through your own meticulous methods, to generate the regulation list.

And perhaps also address whether you believe it likely that appropriately trained employees at CYDY and BP companies would have conducted a similar analysis of LL.

---

Quote:

---

I assume that the LL regulation list is the foundation for the disease list.

Quote:

---

The disease list came first and I was keeping track of what leronlimab was regulating in my head but it was becoming a bit unwieldy so I decided to write them down. The list is only a fraction of what leronlimab regulates. At one time I thought of tracking down the complete pathways of everything connected to CCR5 but that could take a couple of years.

---

---

Quote:

---

But what is the source/foundation for the regulation list? You obviously had to have had something to work with that permitted you to gain such insights regarding the MOA of a particular drug.

Quote:

---

The source was reading thousands upon thousands of medical white papers and study and trial results. Luckily I can be single-minded when I want to know something, time on my hands and a bit of insomnia.]

---

---

Quote:

---

If so, I apologize, but it strikes me that now might be a good time for you to post (or remind us), in as elementary a manner as possible, regarding the source materials that have allowed you, through your own meticulous methods, to generate the regulation list.

Quote:

---

I would have to go back and track down all of those papers and quote cites. It's the only way to do it right. That would be massively time consuming and I would rather spend my time on something else.

This all started out in 2019 with me wanting to know how good leronlimab actually was in HIV before I invested. Then I decided to look at cancer since it seemed odd to me at the time that an HIV drug would work in it. Which led me down a very deep rabbit hole of how the CCR5 receptor actually worked and what leronlimab was capable of.

---

---

Quote:

---

And perhaps also address whether you believe it likely that appropriately trained employees at CYDY and BP companies would have conducted a similar analysis of LL.

Quote:

---

Most of those employees professional lives are involved in their own little niches that do not involve CCR5. The only ones that probably have decent knowledge would be the maraviroc team at Pfizer and they might not realize that leronlimab is much better than maraviroc. There have been a large amount of studies and trials involving maraviroc but Pfizer doesn't seem to be seriously following up on indications. Possibly because of the liver toxicity or maybe because maraviroc sales in HIV are awful.

---

---